AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05342272
Drug: Betaine taurine PVP gel
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
Trial: NCT00523120
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical solution used in ear 5 drops 8 3/day
Trial: NCT01286740
Drug: FTC/RPV/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
Trial: NCT00523120
Drug: dexotc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aural drops
Trial: NCT00965575
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
Trial: NCT00965575
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo. Taken 30 minutes prior to bedtime for four weeks.
Trial: NCT01732770
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg administered by intravenous infusion once a year
Trial: NCT01732770
Drug: Placebo to Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by intravenous infusion once a year
Trial: NCT01096693
Drug: Urocortin 2, Urocortin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3.
Trial: NCT01096693
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Trial: NCT01862302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
Trial: NCT00666224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
Trial: NCT04685265
Drug: anle138b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule containing excipient and anle138b
Trial: NCT04685265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule containing excipient
Trial: NCT01598909
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of Arnica ointment, twice a day, for the period of one week.
Trial: NCT03956212
Drug: Doxycycline 7 days
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
Trial: NCT03956212
Drug: Doxycycline 14 days
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
Trial: NCT00547976
Drug: [C-11]PBR28
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02593669
Drug: Viscoelastic materials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: viscoelastic materials are used to protect corneal endothelial cells.
Trial: NCT00684970
Drug: Hamsa-1™ TL-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily Hamsa-1™ TL-118
Trial: NCT02780362
Drug: Prodactariv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 60 mg Daclatasvir
Trial: NCT02780362
Drug: Clatazev
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 60 mg Daclatasvir
Trial: NCT01117441
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: see detailed protocol description
Trial: NCT01944735
Drug: CTX-4430
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
Trial: NCT02161991
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
Trial: NCT01117441
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see detailed protocol description
Trial: NCT01117441
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see detailed protocol description
Trial: NCT01944735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
Trial: NCT01183949
Drug: AT7519M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose.
Trial: NCT03255551
Drug: Amosartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
Trial: NCT01117441
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: see detailed protocol description
Trial: NCT00705367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion, Intravenous, single dose, Day 1
Trial: NCT00385138
Drug: Placebo bolus & placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Trial: NCT00385138
Drug: Placebo capsules - end of PCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
Trial: NCT00385138
Drug: Placebo capsules - end of infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Trial: NCT00491582
Drug: Growth hormone replacement therapy in growth hormone deficient patients only.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
Trial: NCT00826111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
Trial: NCT02805725
Drug: Phase 1: Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
Trial: NCT01062945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching administration of a placebo pill.
Trial: NCT01610336
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
Trial: NCT00928564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml of saline at each block site.
Trial: NCT00741013
Drug: placebo pill and placebo IV
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Trial: NCT00741013
Drug: Lovastatin pill and placebo IV
RxNorm normalized name: lovastatin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Trial: NCT00462865
Drug: Gemcitabine and Capecitabine and Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
Trial: NCT00730080
Drug: Sapropterin (Kuvan)
RxNorm normalized name: sapropterin Oral Tablet [Kuvan]
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Trial: NCT01496469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
Trial: NCT02002741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
Trial: NCT00863863
Drug: Grifulvin V® 125 mg/5 mL Suspension, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
Trial: NCT02328287
Drug: ALLOB®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
Trial: NCT02544919
Drug: SMOF lipid (SMOFLIPID) pre treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Arm
Trial: NCT02253953
Drug: BILR 355 BS, D1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D4
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D6
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D8
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: BILR 355 BS, D10
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02775448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03833063
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glabellar injections with sodium chloride
Trial: NCT02312050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00315003
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00315003
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00438321
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01212250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
Trial: NCT01402024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule).
Trial: NCT03464019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Trial: NCT00767806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily orally for 12 weeks
Trial: NCT02733471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01626092
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
Trial: NCT02141542
Drug: MEDI3617
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01130064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 3 weeks via intravenous infusion
Trial: NCT03113253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride to mimic tranexamic acid
Trial: NCT03260595
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT01376349
Drug: prasterone
RxNorm normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied vaginally
Trial: NCT02630511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consists of inhaling humidified air
Trial: NCT00668603
Drug: 17-b-estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg oral daily for 6 months
Trial: NCT00059839
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00059839
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT00059839
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and intrathecally
Trial: NCT01835197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
Trial: NCT01835197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
Trial: NCT01835197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
Trial: NCT01835197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
Trial: NCT01835197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
Trial: NCT00668603
Drug: 17-b-estradiol + medroxyprogeterone acetate
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg E2 + 5mg MPA daily for 6 months
Trial: NCT00668603
Drug: 17-b-estradiol hemihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg skin gel daily for 6 months
Trial: NCT00668603
Drug: placebo pill + gel
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily for 6 months
Trial: NCT00818389
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an inactive substance
Trial: NCT03150316
Drug: Treat Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
Trial: NCT00165633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, orally, three times a day, after meals.
Trial: NCT00312325
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01336413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as active comparator, except placebo dispensed.
Trial: NCT02287376
Drug: Diclofenac Potassium for Oral Solution
RxNorm normalized name: Diclofenac Potassium for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID
Trial: NCT02249767
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of acne once daily in evening
Trial: NCT02251925
Drug: administration of 6 mg Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
Trial: NCT04393025
Drug: Optimum medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimum Medical treatment
Trial: NCT02652156
Drug: Exparel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
Trial: NCT00342849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no